Cardiometabolic Monitoring Products Market Size, Share, Trends and Forecast, 2026-2035

Global Cardiometabolic Monitoring Products Market Size, Share & Trends Analysis Report By Product Type, By Indication, By End-user, By Region, And Segment Forecasts, 2026 - 2035

Last Updated: || Author: Akshay Reddy || Reviewed: Akshay Reddy || SKU: MD4154

Buy any syndicated report and get free complimentary customization of up to 20% of the Report and an interactive dashboard.

Report Summary
Table of Contents
List of Tables & Figures

Market Size 2035

USD 113.77 billion

CAGR (2026-2035)

8.9% CAGR

Dominating Region

North America 42.5%

by End-User

Hospitals & clinics 43%

Cardiometabolic Monitoring Products Market Overview

The global cardiometabolic monitoring products market was valued at USD 48.50 billion in 2025 and is forecast to reach USD 113.77 billion by 2035, expanding at an 8.9% CAGR during 2026-2035. The market includes hardware, sensors, consumables and dedicated software used to monitor glucose, cardiac rhythm and function, blood pressure, lipids and cardiometabolic body-composition indicators. General wellness wearables without a validated cardiometabolic measurement function, imaging systems, therapeutic implants and laboratory analysers used outside cardiometabolic testing are excluded.

The market is changing from periodic measurement toward longitudinal monitoring. Continuous glucose monitoring has established the commercial model: recurring sensors, app-based interpretation, remote data sharing and reimbursement tied to clinical use. Cardiac monitoring is following the same direction through extended-wear ECG patches, mobile cardiac telemetry and hospital-to-home platforms. Blood-pressure products are moving from isolated readings to connected measurements combined with atrial-fibrillation screening, while body-composition devices are gaining value through multi-metric trend analysis.

Blood-glucose monitoring remained the largest product category with 37.3% of 2025 revenue, equal to USD 18.09 billion. Abbott alone reported USD 7.998 billion in 2025 diabetes-care sales, while Dexcom generated USD 4.662 billion, demonstrating the scale of recurring biosensor revenue. Cardiac monitoring represented the second-largest product pool. Data integration, reimbursement coverage, sensor life, accuracy, clinical workflow compatibility and the ability to convert alerts into intervention now determine competitive position.

Market Key Highlights

  • Blood-glucose monitoring led with 37.3%, or USD 18.09 billion, in 2025.
  • North America held 42.5% of global revenue, equal to USD 20.61 billion.
  • Hospitals and clinics represented 43.0%, or USD 20.86 billion, of end-user spending.
  • Home-care and self-monitoring generated 34.0%, equal to USD 16.49 billion.
  • Diabetes was the largest indication with 40.5%, or USD 19.64 billion.
  • Wearable and continuous systems represented 39.0% of revenue and are forecast to exceed half of the market before 2032.
  • Asia-Pacific held 23.0% in 2025 and is forecast to record the fastest regional CAGR through 2035.

Market Dynamics

Continuous monitoring is replacing isolated measurements

The strongest growth comes from devices that generate a trend rather than a single reading. Abbott's Libre systems and Dexcom's G7 platform have normalised recurring sensor replacement and automatic data transfer. Abbott's 2025 diabetes-care revenue increased 17.5% to USD 7.998 billion, while Dexcom revenue rose 16% to USD 4.662 billion. These growth rates exceeded the broader medical-device market and show that monitoring frequency, convenience and reimbursement can expand both patient use and revenue per monitored person.

The model is extending beyond glucose. Extended-wear ECG patches can monitor intermittent arrhythmias that short Holter tests may miss. Continuous non-invasive blood-pressure devices and multiparameter patches can keep patients visible after discharge. This transition changes purchasing criteria from device price to total monitored days, diagnostic yield, adherence, clinician review burden and time to intervention.

Multi-analyte sensing is widening the clinical value of a single wearable

Abbott received CE marking in May 2026 for Libre Duo, a sensor measuring glucose and ketones every minute. The FDA approved Libre Duo 10 Day in August, with a US launch expected in December 2026. Combining glucose and ketone data can support daily diabetes management while providing earlier visibility into rising ketones linked to diabetic ketoacidosis. Multi-analyte sensing raises the clinical value of each sensor without requiring another wearable location.

The same architecture can extend toward lactate and other biomarkers, but commercial success will depend on analytical reliability and whether the extra signal changes treatment. Adding metrics without a defined clinical action risks creating alarm burden rather than improved outcomes.

Reimbursement is becoming a product-launch requirement

The 2026 Canadian launch of Dexcom G7 15 Day illustrates the importance of coordinated access. The system entered with public reimbursement for eligible users and expected private-plan coverage. Device duration of up to 15.5 days reduces sensor changes and can improve monthly economics, but coverage determines the addressable population.

Coverage is expanding from intensive insulin users toward type 2 diabetes managed without insulin, prediabetes and broader metabolic monitoring. The commercial boundary between prescription devices and consumer biowearables is therefore becoming less distinct. Companies must maintain separate claims, evidence and data-governance models for clinical and wellness use.

Hospital-to-home monitoring is consolidating

iRhythm completed its acquisition of VitalConnect in October 2026, expanding from ambulatory ECG into mobile cardiac telemetry, inpatient surveillance and continuous multi-vital monitoring. Philips added six partners to its open patient-monitoring ecosystem in August, integrating wearable blood pressure, ECG, oxygen saturation, respiration and temperature data.

These moves show that health systems want fewer disconnected dashboards. Platform value will depend on enterprise integration, centralised review, workflow routing and the ability to maintain monitoring across admission, discharge and recovery. Hardware suppliers without interoperable software may face pressure to partner or become acquisition targets.

Alert quality is becoming more important than data volume

Continuous devices create dense datasets, but health systems have limited capacity to review false or low-priority alerts. AI-based risk prediction, adaptive thresholds and episode summarisation can reduce review time. Roche's Accu-Chek SmartGuide digital functions include prediction of nighttime hypoglycaemia, low glucose and broader glucose trends. The commercial question is whether algorithms improve intervention rates and outcomes without concealing clinically relevant events.

Cybersecurity, model validation, data residency and change control are becoming procurement conditions. An algorithm update can alter clinical behaviour even when sensor hardware remains unchanged, making post-market surveillance and transparent performance reporting essential.

Market Scope

MetricsDetails
CAGR8.9%
Market Size Available for Years2024-2035
Estimation Forecast Period2026-2035
Revenue UnitsValue (US$ Mn) 
Segments CoveredProduct Type, Indication, End User
Regions CoveredNorth America, Europe, Asia-Pacific, South America, and Middle East & Africa
Largest RegionNorth America
Fastest Growing RegionAsia-Pacific
Report Insights CoveredCompetitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights.

For more details on this report – Request for Sample

Market Segmentation Analysis

By Product Type

Blood-glucose monitoring products accounted for 37.3% of global 2025 revenue, equal to USD 18.09 billion. Continuous glucose monitors drive category expansion through recurring sensor sales, while blood-glucose meters and strips remain important in markets where reimbursement, affordability or clinical practice limits CGM use. The category includes prescription CGM, over-the-counter biosensors, meters, strips, lancets and dedicated data applications.

Cardiac monitoring products held 26.0%, or USD 12.61 billion. ECG systems, Holter monitors, event recorders, mobile cardiac telemetry, extended-wear patches and remote cardiac-monitoring software form this segment. ECG and Holter products remain the largest cardiac-monitoring subgroup, but patches and telemetry are gaining because they increase monitoring duration outside hospital settings.

Blood-pressure monitoring represented 18.0%, equal to USD 8.73 billion. Connected upper-arm monitors lead home use, while ambulatory, bedside and continuous non-invasive systems serve clinical workflows. OMRON has sold more than 400 million home blood-pressure monitors globally, indicating the installed base available for connected services and AFib screening.

Lipid and cholesterol monitoring generated 7.0%, or USD 3.40 billion. The segment covers point-of-care and self-testing systems used to measure total cholesterol and lipid fractions. Body-composition and other cardiometabolic monitoring products supplied 11.7%, equal to USD 5.67 billion, including clinically positioned smart scales, visceral-fat assessment, ketone monitoring and multiparameter devices.

By Monitoring Mode

Wearable and continuous products represented 39.0% of 2025 revenue, or USD 18.92 billion. Their share is forecast to rise as sensor duration increases and use expands into type 2 diabetes, post-discharge cardiac care and hospital-at-home programmes. Connected spot-monitoring products held 34.0%, or USD 16.49 billion, supported by app-linked glucose meters, blood-pressure monitors, scales and point-of-care devices.

Conventional non-connected products accounted for 27.0%, equal to USD 13.10 billion. Their revenue share will decline, but they will remain important where connectivity is unnecessary, digital infrastructure is limited or low unit cost is the primary purchasing criterion.

By Indication

Diabetes led with 40.5% of 2025 revenue, equal to USD 19.64 billion. The share exceeds the glucose product percentage because diabetes management can include ketone, blood-pressure, lipid and cardiac-risk monitoring. Arrhythmia and other cardiovascular disease represented 25.0%, or USD 12.13 billion, driven by AF detection, post-ablation surveillance, heart-failure monitoring and post-discharge care.

Hypertension generated 18.5%, equal to USD 8.97 billion. Obesity and metabolic syndrome accounted for 10.0%, or USD 4.85 billion, as connected body-composition and metabolic devices move into weight-management pathways. Dyslipidaemia and other cardiometabolic conditions supplied 6.0%, or USD 2.91 billion.

By End User

Hospitals and clinics controlled 43.0% of 2025 revenue, equal to USD 20.86 billion. They purchase bedside monitoring, ECG systems, ambulatory services, point-of-care testing and enterprise software. Home care and self-monitoring represented 34.0%, or USD 16.49 billion, supported by CGM, blood-pressure monitors, smart scales and app-connected devices.

Diagnostic centres and ambulatory monitoring providers held 13.0%, or USD 6.31 billion. Pharmacies and retail health channels represented 6.0%, or USD 2.91 billion, while research organisations, employers and other users accounted for 4.0%, equal to USD 1.94 billion.

Regional and Country Analysis

North America

North America led with 42.5% of 2025 revenue, equal to USD 20.61 billion. The United States alone represented an estimated 38.0% of the global market, or USD 18.43 billion. CGM reimbursement, high diabetes prevalence, ambulatory ECG adoption, remote patient-monitoring infrastructure and a strong digital-health ecosystem support the region.

The United States is moving beyond prescription-only monitoring. Over-the-counter glucose biosensors have opened metabolic data to adults without intensive insulin therapy, while cardiac-monitoring acquisitions are connecting ambulatory, inpatient and hospital-to-home care. Canada contributed close to USD 1.36 billion in 2025 and is benefiting from coordinated public and private CGM reimbursement.

Europe

Europe accounted for 26.5%, or USD 12.85 billion, in 2025. Germany represented 5.3% of global revenue, equal to USD 2.57 billion, followed by the UK at 4.6%, or USD 2.23 billion. National reimbursement differences create uneven adoption, but the region has strong demand for home blood-pressure monitoring, diabetes technologies and remote cardiac care.

CE marking for dual glucose-ketone sensing and the EUR 27.6 million EXIT-CVD project show Europe's role in clinical validation. EXIT-CVD will conduct 22 studies involving more than 14,000 patients across 17 countries, including remote heart-failure monitoring and digital early detection.

Asia-Pacific

Asia-Pacific held 23.0%, equal to USD 11.16 billion, and is expected to grow at the fastest rate. China represented 8.0% of global revenue, or USD 3.88 billion, while Japan held 5.8%, equal to USD 2.81 billion. Large diabetes and hypertension populations create volume, but reimbursement and out-of-pocket affordability shape the product mix.

Japan combines an ageing population with strong adoption of validated home monitoring. OMRON's global blood-pressure franchise and connected ECG capabilities support regional product development. In China, competitive pricing and domestic device manufacturers constrain premium international brands, but connected chronic-disease programmes and hospital digitisation expand the addressable base.

Competitive Landscape and Company Profiles

Abbott Laboratories

Abbott operates across continuous glucose monitoring, rhythm management and connected cardiovascular care. Its FreeStyle Libre ecosystem includes sensors, readers, mobile applications and clinician data tools. The company reported USD 7.998 billion in 2025 diabetes-care revenue, split between USD 3.181 billion in the United States and USD 4.817 billion internationally.

Libre Duo extends Abbott's platform into continuous glucose-ketone monitoring. Abbott is also widening access through consumer and type 2 diabetes products such as Lingo and Libre Rio. Its competitive advantage comes from sensor scale, global reimbursement, pharmacy distribution and digital integration. The principal strategic risk is maintaining accuracy, supply reliability and payer value as competitors extend wear duration.

Dexcom

Dexcom develops continuous glucose-monitoring systems and related software. Its portfolio includes G7, G7 15 Day and Stelo, an over-the-counter biosensor for adults not using insulin. Dexcom reported USD 4.662 billion in 2025 revenue, up 16%, with both US and international revenue growing at double-digit rates.

The G7 15 Day offers up to 15.5 days of wear and an overall MARD of 8.0% in its Canadian authorisation. Longer duration reduces monthly sensor changes and can improve convenience and channel economics. Dexcom's opportunity lies in broader type 2 diabetes coverage and consumer metabolic health, while competition is intensifying around price, sensor life and automated-insulin-delivery interoperability.

OMRON Healthcare

OMRON Healthcare supplies home blood-pressure monitors, ECG devices, body-composition monitors and connected health services. It has sold more than 400 million home blood-pressure monitors across more than 130 countries. Healthcare-business revenue was JPY 145.3 billion for the year ended March 2026.

The company is adding AFib screening to routine blood-pressure measurement and linking devices through OMRON Connect. In October 2026, it introduced the VIVA 360+ Full-Body Smart Scale in the United States with up to 18 metrics and an Athlete Mode. OMRON's installed base is a strong platform for longitudinal hypertension and metabolic-risk services, but low-cost competition can limit hardware margins.

Philips

Philips provides hospital patient monitoring, mobile cardiac telemetry, central monitoring software and connected-care infrastructure. Its monitoring ecosystem connects bedside, wearable and out-of-hospital technologies through enterprise platforms such as PIC iX. Mobile Cardiac Telemetry can support remote cardiac monitoring for up to 30 days after inpatient or emergency evaluation.

In August 2026, Philips added collaborations with six monitoring companies covering continuous blood pressure, ECG, oxygen saturation, respiration, temperature and hospital-at-home workflows. The strategy positions Philips as an orchestration layer across multiple devices. Success depends on interoperability, cybersecurity and reducing the number of unprioritised alerts presented to clinical teams.

Recent Developments

  • October 28, 2026: Dexcom announced the Canadian launch of G7 15 Day for November, supported by public reimbursement for eligible users and expanding private-plan coverage.
  • October 15, 2026: Philips and the EXIT-CVD consortium launched a five-year, EUR 27.6 million programme covering 22 studies and more than 14,000 cardiovascular patients.
  • October 13, 2026: OMRON launched VIVA 360+ in the United States, providing up to 18 body metrics through a connected full-body smart scale.
  • October 5, 2026: iRhythm completed its acquisition of VitalConnect, adding mobile cardiac telemetry and continuous multiparameter monitoring across ambulatory and hospital-to-home care.
  • August 2026: The US FDA approved Abbott's Libre Duo 10 Day dual glucose-ketone sensing system, with commercial launch planned for December.
  • August 6, 2026: Philips expanded its monitoring ecosystem through six wearable and out-of-hospital technology collaborations.
  • May 27, 2026: Abbott received CE marking for Libre Duo and Libre Duo 10 Day, enabling continuous glucose and ketone readings every minute.

Strategic Key Takeaways

  • Recurring sensors are the market's primary revenue engine. Abbott and Dexcom generated more than USD 12.6 billion in combined 2025 diabetes-monitoring revenue.
  • Multi-analyte sensing must connect to a clinical action. Glucose-ketone integration has a defined role in identifying rising diabetic-ketoacidosis risk.
  • Reimbursement should be planned with the launch, not after it. Dexcom's Canadian rollout combines product availability with public and private coverage.
  • Hospital-to-home platforms are becoming acquisition targets. iRhythm's VitalConnect transaction adds monitoring settings and vital signs rather than another isolated device.
  • Alert management will determine enterprise adoption. Systems that summarise episodes and prioritise intervention can create more value than platforms that only increase data volume.
  • Asia-Pacific requires tiered portfolios. Premium continuous systems and affordable connected spot monitors address different reimbursement and income conditions.
  • Consumer cardiometabolic products need strict claim separation. Wellness insights, screening functions and medical diagnosis require different evidence, labelling and regulatory controls.

Why Purchase the Report?

  • To visualize the global cardiometabolic monitoring products market segmentation based on product type, indication, end user and region as well as understand key commercial assets and players.
  • identify commercial opportunities by analyzing trends and co-development.
  • excel data sheet with numerous data points of the cardiometabolic monitoring products market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global cardiometabolic monitoring products market report would provide approximately 64 tables, 61 figures and 286 pages.

Target Audience

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies
Save 31% on all licenses
Single User$4350$2999Corporate$7850$5412

Free 20% customization + dashboard

Trusted by Global Leaders

ADM
Africa Climate Ventures
Algalif
Amcor
Arysta
Asahi
BASF
Baycurrent
BAYER
BioCartis
BIORAD
BRAUN
Budenheim
Daikin
Deerland
DENSO
DUPONT
Epax
FrieslandCampina
FUJIFILM
Hitachi
HONDA
HUAWEI
Inorganic Ventures
ITOCHU
JFE Steel
KAMEDA
Kaneka
KERRY
Marubeni
Meiji
Mitsubishi
MITSUI & Co
Morinaga
NFIT
NIPRO
Pfizer
Plexus
Polaris
Probiotical
RKW
Kearney
Takeda
Sensia
SACCO system
SEKISUI
SKYTILLER
Sony
Sumitomo Chemical
Symrise
Tate & Lyle
Teijin
thyssenkrupp
TORAY
TOSHIBA
Unilever
Xerox
ADM
Africa Climate Ventures
Algalif
Amcor
Arysta
Asahi
BASF
Baycurrent
BAYER
BioCartis
BIORAD
BRAUN
Budenheim
Daikin
Deerland
DENSO
DUPONT
Epax
FrieslandCampina
FUJIFILM
Hitachi
HONDA
HUAWEI
Inorganic Ventures
ITOCHU
JFE Steel
KAMEDA
Kaneka
KERRY
Marubeni
Meiji
Mitsubishi
MITSUI & Co
Morinaga
NFIT
NIPRO
Pfizer
Plexus
Polaris
Probiotical
RKW
Kearney
Takeda
Sensia
SACCO system
SEKISUI
SKYTILLER
Sony
Sumitomo Chemical
Symrise
Tate & Lyle
Teijin
thyssenkrupp
TORAY
TOSHIBA
Unilever
Xerox
FAQ’s

  • The cardiometabolic monitoring products market was valued at USD 48.50 billion in 2025 and is forecast to reach USD 113.77 billion by 2035.

  • Blood-glucose monitoring led with 37.3%, equal to USD 18.09 billion in 2025.

  • North America held 42.5%, or USD 20.61 billion, in 2025.

  • Asia-Pacific is expected to record the fastest growth through 2035.

  • Hospitals and clinics represented 43.0% of 2025 revenue.

  • Home care and self-monitoring generated USD 16.49 billion, or 34.0%, in 2025.

  • They provide trends, alerts and remote data rather than isolated readings, increasing clinical utility and recurring sensor revenue.

  • It uses one system to measure more than one biomarker. Libre Duo, for example, continuously measures glucose and ketones.

  • The report profiles Abbott, Dexcom, OMRON Healthcare and Philips.

  • Recurring sensor costs, unequal reimbursement, alert burden, cybersecurity, interoperability gaps and limited digital infrastructure constrain adoption.

  • Only products with a defined cardiometabolic measurement or monitoring function are included. General activity trackers without such functionality are excluded.
What Our Clients Say About this Report
Melissa Grant
Director of Connected Cardiometabolic Care, United States
12 Sep, 2026
5/5
The report separates sensor revenue from conventional monitoring and explains how reimbursement, wear duration and alert workflows shape adoption. The quantified US analysis is useful for portfolio and access planning.
Kenji Nakamura
General Manager of Digital Health Strategy, Japan
10 Nov, 2026
5/5
The Japan and Asia-Pacific sections connect home blood-pressure monitoring, metabolic risk and digital integration without treating the region as one uniform market. The company analysis provides a practical view of platform competition.
PDF
DataM
Cardiometabolic Monitoring Products Market Report
SKU: MD4154

Data-Backed Decisions Start Here

Explore how our research empowers industry leaders to cut through uncertainty. Get a free sample of this report or tailor it precisely to your business needs.

ISO 27001 Certified
ADM
Africa Climate Ventures
Algalif
Amcor
Arysta
Asahi
BASF
Baycurrent
BAYER
BioCartis
BIORAD
BRAUN
Budenheim
Daikin
Deerland
DENSO
DUPONT
Epax
FrieslandCampina
FUJIFILM
Hitachi
HONDA
HUAWEI
Inorganic Ventures
ITOCHU
JFE Steel
KAMEDA
Kaneka
KERRY
Marubeni
Meiji
Mitsubishi
MITSUI & Co
Morinaga
NFIT
NIPRO
Pfizer
Plexus
Polaris
Probiotical
RKW
Kearney
Takeda
Sensia
SACCO system
SEKISUI
SKYTILLER
Sony
Sumitomo Chemical
Symrise
Tate & Lyle
Teijin
thyssenkrupp
TORAY
TOSHIBA
Unilever
Xerox
ADM
Africa Climate Ventures
Algalif
Amcor
Arysta
Asahi
BASF
Baycurrent
BAYER
BioCartis
BIORAD
BRAUN
Budenheim
Daikin
Deerland
DENSO
DUPONT
Epax
FrieslandCampina
FUJIFILM
Hitachi
HONDA
HUAWEI
Inorganic Ventures
ITOCHU
JFE Steel
KAMEDA
Kaneka
KERRY
Marubeni
Meiji
Mitsubishi
MITSUI & Co
Morinaga
NFIT
NIPRO
Pfizer
Plexus
Polaris
Probiotical
RKW
Kearney
Takeda
Sensia
SACCO system
SEKISUI
SKYTILLER
Sony
Sumitomo Chemical
Symrise
Tate & Lyle
Teijin
thyssenkrupp
TORAY
TOSHIBA
Unilever
Xerox